Form 4 for IONS IONIS PHARMACEUTICALS INC
Accepted 2026-06-16 17:26:18 ET · period of report 2026-06-12 · accession 0000874015-26-000208 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-06-16 17:26 | 2026-06-12 | IONS | Kordasiewicz Holly B. | EVP, Chief Development Off | M - OptEx | $53.97 | +60.8K | 83.3K | +271% | +$3.28M |
| DMT | 2026-06-16 17:26 | 2026-06-12 | IONS | Kordasiewicz Holly B. | EVP, Chief Development Off | S - Sale+OE | $73.41 | -60.8K | 22.5K | -73% | -$4.47M |
| DMT | 2026-06-16 17:26 | 2026-06-12 | IONS | Kordasiewicz Holly B. | EVP, Chief Development Off | M - OptEx | $0.00 | -60.8K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-12 | M | A | 7,951 | $60.89 | 30,409 | D | — | — | |
| 2 | Common | Common Stock | 2026-06-12 | M | A | 21,000 | $60.89 | 51,409 | D | — | — | |
| 3 | Common | Common Stock | 2026-06-12 | M | A | 12,000 | $32.60 | 63,409 | D | — | — | |
| 4 | Common | Common Stock | 2026-06-12 | M | A | 19,895 | $56.78 | 83,304 | D | — | — | |
| 5 | Common | Common Stock | 2026-06-12 | S | D | 41,004 | $73.09 | 42,300 | D | — | — | (F1) Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 13, 2026 (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.68 to $73.67 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. |
| 6 | Common | Common Stock | 2026-06-12 | S | D | 19,842 | $74.05 | 22,458 | D | — | — | (F1) Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 13, 2026 (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.735 to $74.28 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. |
| 7 | Derivative | Non-Qualified Stock Option (right to buy) | 2026-06-12 | M | D | 12,000 | $0.00 | 0 | D | $32.60 · 2023-01-03 to 2032-01-02 | 12,000 Common Stock | |
| 8 | Derivative | Non-Qualified Stock Option (right to buy) | 2026-06-12 | M | D | 19,895 | $0.00 | 0 | D | $56.78 · 2022-01-04 to 2028-01-03 | 19,895 Common Stock | |
| 9 | Derivative | Non-Qualified Stock Option (right to buy) | 2026-06-12 | M | D | 7,951 | $0.00 | 21,000 | D | $60.89 · 2021-01-02 to 2027-01-01 | 7,951 Common Stock | |
| 10 | Derivative | Non-Qualified Stock Option (right to buy) | 2026-06-12 | M | D | 21,000 | $0.00 | 0 | D | $60.89 · 2021-01-02 to 2027-01-01 | 21,000 Common Stock |